NewEdge Advisors LLC Sells 6,643 Shares of Halozyme Therapeutics, Inc. $HALO

NewEdge Advisors LLC decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 57.4% in the first quarter, Holdings Channel reports. The firm owned 4,933 shares of the biopharmaceutical company’s stock after selling 6,643 shares during the period. NewEdge Advisors LLC’s holdings in Halozyme Therapeutics were worth $319,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of HALO. Arrowstreet Capital Limited Partnership increased its holdings in Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after purchasing an additional 749,484 shares during the period. Dimensional Fund Advisors LP raised its position in Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after purchasing an additional 25,731 shares in the last quarter. Norges Bank purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth $128,201,000. William Blair Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth $124,031,000. Finally, Federated Hermes Inc. grew its position in shares of Halozyme Therapeutics by 8.5% during the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after buying an additional 123,917 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on HALO. Citizens Jmp raised their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. TD Cowen increased their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $83.00 to $110.00 in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $108.17 on Monday. The company has a 50 day moving average of $83.19 and a two-hundred day moving average of $73.74. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $108.49. The company has a market cap of $12.28 billion, a price-to-earnings ratio of 32.29, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same period in the prior year, the firm posted $1.54 earnings per share. The business’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. This represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,103 shares of company stock worth $5,226,496 in the last ninety days. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.